Chronic Migraine, Headache Clinical Trial
Official title:
Assessing the Safety and Efficacy of Utilizing CGRPmAb Fremanezumab (Ajovy) in Chronic Migraine Patients Currently on Monotherapy OnabotulinumtoxinA (Botox).
Chronic migraine patients treated with OnabotulinumtoxinA may experience breakthrough headaches, especially toward the end of their 12-week therapy. The addition of a CGRPmAb could help in decreasing or eliminating these episodes, but this combination is considered "experimental" by many payers, which often leads to a denial of coverage. Currently, there is no reference in the literature or data to support the treatment of chronic migraine with OnabotulinumtoxinA and CGRPmAbs (Aimovig, Ajovy, Emgality or Vyepti) combination therapy. This has resulted in many patients and providers having to settle for one or the other. Investigators hopes to provide crucial data and findings to support the addition of CGRPmAb in some chronic migraine patients currently on monotherapy OnabotulinumtoxinA.
Phase IV prospective open label interventional clinical study evaluating beneficial outcomes of the addition of CGRPmAb Fremanezumab in chronic migraine patients currently on monotherapy OnabotulinumtoxinA. The investigators will enroll patients with ≥2 OnabotulinumtoxinA treatments at screening with a history of ≥8 monthly migraine days (average from 3 previous months prior to enrollment (visit 2)). Between visit 1 (screening) and visit 3, all patients will be on monotherapy OnabotulinumtoxinA for up to 12 weeks. Patients will be administered a total of 2 OnabotulinumtoxinA treatments for the duration of the entire study. OnabotulinumtoxinA treatment will be administered at Day 1 (visit 2) and Day 90 (visit 4), with a treatment window ±6 days. OnabotulinumtoxinA treatment of 155 units or 195 units will be injected intramuscularly over 31-35 injections of head and neck muscles. Study patients must be on a stable OnabotulinumtoxinA dose at screening (visit 1), that dose will be used for the duration of the study. Dosing paradigm: At Day 7 (visit 3) study patients will initiate CGRPmAbs treatment of Fremanezumab 225mg/1.5mL monthly dose for 6 months. Doses will be taken on Days: 7, 37, 67, 97, 127, and 157; with a treatment window ±2 days. • OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL = 50 Rescue medication will be allowed to treat acute migraine attacks consistent with the parameters referenced in previous CGRP clinical trials. Acute rescue utilizing -gepants will be limited to no more than 5 days per month. No use of -gepants as a preventative treatment for at least 1 week prior to screening (visit 1) and throughout the duration of the study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04520425 -
Osteopathic Manipulative Techniques for the Treatment of Chronic Migraine Headaches
|
N/A | |
Recruiting |
NCT06247592 -
Pulse Radiofrequency and Occipital Nerve Block for Chronic Migraine Patients
|
N/A | |
Recruiting |
NCT06133491 -
Open Label, 6-month Study for High Frequency and Chronic Migraine,
|
||
Recruiting |
NCT04989413 -
Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg vs Placebo as Adjuvant Treatment in Chronic Migraine -
|
Phase 4 | |
Recruiting |
NCT06138171 -
Personality, Defences, Central Sensitization, and Trauma in Women With Chronic Migraine, Fibromyalgia, and Vulvodynia
|
||
Active, not recruiting |
NCT06109389 -
The Efficacy Of Lidocaine Infusion IN Chronic Unilateral Migraine Headache
|
Phase 2 | |
Completed |
NCT04871581 -
Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device
|
N/A | |
Withdrawn |
NCT01749423 -
A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
|
N/A | |
Terminated |
NCT04349176 -
Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?
|
Phase 3 | |
Completed |
NCT05381129 -
The Effect of Accompanying Temporomandibular Joint Dysfunction in Patients With Chronic Migraine
|
N/A | |
Completed |
NCT05381012 -
Fibromyalgia Syndrome on Patients With Chronic Migraine
|
N/A | |
Withdrawn |
NCT03465826 -
Developing a Mobile Health Pain-Coping Skills Training Program for the Treatment of Chronic Migraine: AIM 4
|
N/A | |
Completed |
NCT03767062 -
Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches
|
N/A | |
Completed |
NCT05748535 -
Effect of Auricular Vagus Nerve Stimulation in Women With Migraine Disease
|
N/A | |
Recruiting |
NCT05313503 -
KETOMIGRAINE: Ketogenic Diet in Drug-resistant Chronic Migraineurs
|
N/A | |
Recruiting |
NCT05079659 -
Rate , Predictors and Outcome of Chronic Migraine
|
||
Completed |
NCT03698409 -
Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.
|
Phase 4 | |
Completed |
NCT06118190 -
Mesotherapy in the Treatment of Chronic Migraine
|
N/A | |
Completed |
NCT04017741 -
A Study Investigating the Efficacy of GON Blocks.
|
Phase 4 | |
Completed |
NCT05679908 -
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
|
Phase 2 |